Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer

Leflunomide (Lef) is an agent used in autoimmune disorders that interferes with DNA synthesis. De Novo pyrimidine synthesis is a mechanism of Gemcitabine (Gem) resistance in pancreatic cancer. This study aims to assess the efficacy and changes in the tumor microenvironment of Lef monotherapy and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Thuy, Nguyen, Vu H., Buettner, Ralf, Morales, Corey, Yang, Lifeng, Wong, Paul, Tsai, Weiman, Salazar, Marcela d'Alincourt, Gil, Ziv, Diamond, Don J, Rabinowitz, Joshua D., Rosen, Steven, Melstrom, Laleh G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241727/
https://www.ncbi.nlm.nih.gov/pubmed/34239352
http://dx.doi.org/10.7150/ijbs.60473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241727/
https://www.ncbi.nlm.nih.gov/pubmed/34239352
http://dx.doi.org/10.7150/ijbs.60473

Ejemplares similares